# LifeBridge Innovations, PBC

Transforming metastatic cancer from a terminal prognosis to a manageable disease like diabetes

## Elevator pitch
When people with cancer get really sick all known medicines stop working and they are told to prepare to die. We are going to change that by building a device just for them. The device makes a therapy proven to work in patients with cancer in just one location, like the lungs, work in more than one location like the lung and liver at the same time. Best of all it treats cancer without making the patients feel sick or tired and they don't lose their hair.

- Canonical URL: https://wefunder.com/LifeBridgeinnovations
- Entity ID: wefunder:company:15376
- Last updated: 2026-06-17T05:01:36Z
- Generated at: 2026-06-17T21:19:50Z

## Quick facts
- Team has 60 devices through FDA, products in 3000 hospitals, 300 yrs combined experience
- Med tech firm sent unsolicited offer to buy us -investor/team unanimously agreed too early to sell
- Granted patents in U.S., Canada, MX, EU, Japan, China, Australia, New Zealand, India, Chile
- $5M raised from friends & family, angels, who know our track record & see a huge market opportunity
- TTF is based on 25 years of proven research. Fixed form approved by the FDA for multiple indications
- On any given day, over 500,000 U.S. patients in their last 36months could benefit from our therapy
- TTF has minimal side effects: no hair loss, no nausea, no fatigue, no chemo brain, etc.
- Committed to serve those who cannot afford it while maintaining industry benchmarked profitability

## Active fundraises
- wefunder:fundraise:73636: 4(a)(6) successful (USD)
- wefunder:fundraise:73637: 4(a)(6) successful (USD)
- wefunder:fundraise:10768: 4(a)(6) successful (USD)
- wefunder:fundraise:47544: 4(a)(6) successful (USD)

## Story
Future projections are not guaranteed

## FAQ
1. **Lifebridge team, you have grabbed my attention today! Do you see - as part of your planned clinical trials, to combine your TTF product with drug therapies that minimizes/eliminates metastasis? I can see this combination as a powerful winning combo.**
   - Hello Kirtson, thank you for your insightful question. We are keeping our eye on new drug therapies that reduce metastases without compromising the immune system. To date most of the TTF used in clinical trials has been in combination with powerful chemo's that often compromise the immune system. What research has documented is that there is a correlation between immune system health and the effectiveness of TTF. One of the main mechanisms of TTF is that it causes cancer cells to produce malf...
2. **It seems much of the future potential is based on Novocure patents expiring in the next few years. Can you clarify if these are fixed term patents that cannot be renewed? If not I would assume they will pay the necessary fees to renew.**
   - Hello Jennifer, thank you for this important question. All the patents in question are fixed term. They cannot be renewed. Patent terms are for 20 years. The first day in the life of a patent is called the "Priority Date". Most of the patents in question have Priority Dates between 2000 and 2002. Sometimes, patents can be extended because the patent office took longer than allowed to do their work. So, if they took 6 months too long, the patent life is given another 6 months. Sometimes new pa...
3. **Hi, you have proposed a 19.5M valuation cap. Could you please share the valuation and terms of Novocure’s buyout offer?**
   - Hello David, Thank you for your question. We have not disclosed which larger company sent us an offer, and the terms of the offer are under NDA.
4. **How can an oncologist obtain information on how this can be used with her patients? What is the cost for the patient and if it can be covered by insurance? How can the creators be contacted? Thank you**
   - Hello Lissette, thank you for your question. We are preparing our device for a pilot clinical trial and then a pivotal trial for final approval. Our device is not yet available for prescriping. TTF is available through Novocure for GBM brain cancer, and Mesotheloma. Your Oncologist can find out more through www.novocure.com
5. **HI team, Great job with progress and the raise so far. Definitely a revolutionary product. Got a few questions before finalizing the investment. 1. Is your device currently in use or still in trail for final approval? 2. If in use, how many devices have been sold? If in trail,...**
   - Hello Arul, thank you for your pertinent questions. Please see the following replies and let me know if you have additional questions. 1. Arul: Is your device currently in use or still in trial for final approval? Peter: We are currently in the FDA approval process. The FDA has approved our clinical trial protocol, allowing us to treat up to 36 patients across 10 different types of cancer in a single basket trial. This approach saves years of research and millions of dollars, compared to runn...

## Team
- Peter F Travers (CEO and Founder)
- Lee Zehngebot M.D. (Medical Advisor)
- Zeev Bomzon PhD (Lead Scientist)
- Ken Watkins (Founding Member and Chief Technologist)
- Scott Krywick (Consulting Software Engineer)
- Timothy Vandermey (Founding Member and Senior Engineer)
- Ping Yeh (CEO VOCxi Health )
- Mike Black (CFO)
- Bud Abt (Finance and Accounting Consultant)
- Scott Hubbard (Advisor)

## Q&A
- Q: What is price per share
  - A: Hi John, The current price per share is $1.04. We anticipate several major inflection points over the next 18–24 months: Within the next 18 months: We aim to secure an Investigational Device Exemption (IDE) from the FDA, which would authorize us to begin our human clinical trial. Shortly after IDE approval: We plan to treat our first cohort of 6 patients. Within 24 months: We expect to complete the full clinical trial. Successfully completing these milestones has historically driven significant increases in valuation for medtech companies at our stage. They represent key de-risking events that validate both the safety of the platform and its therapeutic potential — setting the stage for broader trials, strategic partnerships, and accelerated investor interest.
- Q: Do you know about LSN: https://www.lifesciencenation.com/workshops/
  - A: I was also not aware of this service. Thank you again I will check it out. Peter
- Q: Do you know about LIN: https://www.lifespan.io/longevity-investor-network/
  - A: No I was not Thomas, thank you I will check it out. Peter
- Q: where do I find my documents for my investment?
  - A: Hello Rick, thanks for reaching out. To find your investment documents log into your Wefunder account and navigate to your Wefunder Portfolio 1. Locate Investment Documents: Within the portfolio, you can view the status and payment information for all your investments. If you wish you can download your investment contracts directly from this page .help.wefunder.com+1help.wefunder.com+1help.wefunder.com+1help.wefunder.com+1 If you have any issues or cannot locate a document we can also contact Wefunder's support team at support@wefunder.com for assistance. Please let me know if you have any questions Peter Travers CEO
- Q: HI team, Great job with progress and the raise so far. Definitely a revolutionary product. Got a few questions before finalizing the investment. 1. Is your device currently in use or still in trail for final approval? 2. If in use, how many devices have been sold? If in trail, how much cash burn and how much time do you anticipate before final approval? (You have spoken about trails back in Feb 2022, so would be great if you could highlight the challenges faced in trail and the progress made in the last 3 years) 3. What is the cost per device? What does take for you to manufacture it? 4. What is your current cash in hand and the burn rate? 5. How long do you plan on keeping this raise open? Some of the questions involves numbers, if you would want me to sign an NDA, I would be happy to do one. Thanks a again and looking forwards to investing in your goal.
  - A: Hello Arul, thank you for your pertinent questions. Please see the following replies and let me know if you have additional questions. 1. Arul: Is your device currently in use or still in trial for final approval? Peter: We are currently in the FDA approval process. The FDA has approved our clinical trial protocol, allowing us to treat up to 36 patients across 10 different types of cancer in a single basket trial. This approach saves years of research and millions of dollars, compared to running separate trials for each cancer type. Before we begin our human trials, we need to complete our animal study, which is currently halfway through. We've successfully delivered 1,332 hours of therapy to three animals over a month with no adverse events. The final pathology report is still pending, but there were no concerns noted in the necropsies. Our current timeline shows we will apply for the Investigational Device Exemption (IDE) in September/October 2025, with the first patient enrollment expected by December 2025 or early 2026. Our device is classified as Class 3, not due to its risk, but because it will be used to save lives. ________________________________________ 2. Arul: If in use, how many devices have been sold? Peter: As mentioned above, we are still in the clinical trial phase. Devices are not sold; they will be prescribed by Oncologists for monthly fees. When prescription periods are over, the device is returned and goes through an FDA approved cleaning and refurbishing process for use by the next patient. ________________________________________ 3. Arul: If in trial, how much cash burn and how much time do you anticipate before final approval? Peter: We anticipate completing our trials for final approval by 2028/29. Along the way, we expect valuation increases at key milestones, such as the completion of the animal study, receipt of our IDE, and the successful conclusion of the 36-person trial (around 2026/27). The cost of the first human trial is approximately $5 million. Each step of the process brings us closer to securing the necessary funding, with successful cancer therapies historically attracting significant investment. ________________________________________ 4. Arul: You’ve mentioned trials back in February 2022. Could you share the challenges faced and progress made over the past 3 years? Peter: The biggest challenge has been meeting the FDA’s evolving requirements. Initially, we were asked to complete our animal study on rabbits, similar to the approach used by the company that currently has FDA approval for fixed array TTF. However, halfway through, the FDA changed its policy, requiring us to use swine instead. Pigs presented unique challenges: their rough behavior towards the device and body temperature ranges (101°F–103°F) made it difficult to keep the device cool. We spent 6-10 months developing pig-specific support devices, which have also resulted in innovations that will enhance human therapy. Our animal study is on track to finish by May, with the first three animals already tested. The Last 3 Years – Strengthening Our Team & Intellectual Property Over the past three years, we’ve made significant strides not only in our product development but also in expanding and strengthening our team. This period has seen the addition of two new patents, bringing our total to five granted patents with ten more pending. These advancements have helped protect your investment and position LifeBridge for continued growth. Our Team: We are proud to have built a world-class team of experts who bring a wealth of experience and leadership to LifeBridge: • Scott Krywick, our new VP of Product Development and Head of Programming, made the decision to leave his career at Lockheed Martin to join LifeBridge full-time. His expertise in engineering and product development will be invaluable as we continue to refine and perfect our technology. • Mike Black, our Fractional CFO, has joined us with a proven track record in successfully guiding a Class 3 medical device through the FDA approval process. He was formerly the CEO of a company that commercialized a Class 3 device and sold it to ZOLL Medical Corporation. • Maggie Scheuermann, our Project Manager, brings her expertise in bioengineering, having earned a Master’s degree in the field from California Polytechnic State University, San Luis Obispo. Her technical acumen and leadership are key as we move forward in our development stages. • Michael Hoyos, our Chief Business Officer, comes with exceptional experience from his time at JPMorgan and McKinsey & Company. Michael led high-impact engagements in life sciences, healthcare, and private equity. A cum laude graduate from The Wharton School and holder of an MBA from The University of Chicago Booth School of Business, Michael is enhancing our business strategy and funding efforts. • Finally, we are honored to have Dr. Zeev Bomzon PhD as our Lead Scientist. Dr. Bomzon is widely regarded as one of the world’s top experts in Tumor Treating Fields (TTF), holding 14 patents related to TTF technology and publishing over 30 scientific articles. He was formerly the Director of Science at Novocure, the only other company involved in TTF technology, which is currently valued at over $1.5 billion. Here’s a note from Dr. Bomzon on why he joined LifeBridge: “I am here because the science indicates that LifeBridge has created a breakthrough device with the potential to unleash the full benefit of Tumor Treating Fields and help hundreds of thousands of people, as well as do well for us all.” Zeev Bomzon, PhD Our team’s collective expertise, coupled with our growing intellectual property portfolio, strengthens our position as we work toward delivering life-saving cancer therapies. We’re confident that these additions will be instrumental in the success of LifeBridge. 5. Arul: What is the cost per device? Peter: The cost per device is decreasing as we automate production and build efficiencies. Third-party reimbursement for Tumor Treating Fields (TTF) has been established worldwide, including through Novocure’s efforts. For example, TTF for GBM brain cancer is reimbursed at $15,000 per month by Medicare. Our device will be priced similarly to traditional cancer therapies, maintaining an 85% gross profit margin, which aligns with industry standards. ________________________________________ 6. Arul: What does it take to manufacture the device? Peter: With careful planning, we can produce multiple systems for the trial in about three months. ________________________________________ 7. Arul: What is your current cash in hand and the burn rate? Peter: Our capital raising has been cyclical, with periods of intense fundraising followed by focused development work. This approach has been efficient but sometimes intermittent. To address this, we've hired Michael Hoyos as our Chief Business Officer, who is streamlining our capital raising efforts. We currently have 70 accredited investors who have collectively invested over $5 million in the company. These investors remain committed to our mission. For more details on the fundraising process, you can contact our lead investor, Dr. John Young. ________________________________________ 8. Arul: How long do you plan on keeping this raise open? Peter: The current campaign is scheduled to close on August 6th, but it may close earlier depending on the success of our parallel funding efforts.
- Q: Lifebridge team, you have grabbed my attention today! Do you see - as part of your planned clinical trials, to combine your TTF product with drug therapies that minimizes/eliminates metastasis? I can see this combination as a powerful winning combo.
  - A: Hello Kirtson, thank you for your insightful question. We are keeping our eye on new drug therapies that reduce metastases without compromising the immune system. To date most of the TTF used in clinical trials has been in combination with powerful chemo's that often compromise the immune system. What research has documented is that there is a correlation between immune system health and the effectiveness of TTF. One of the main mechanisms of TTF is that it causes cancer cells to produce malformed daughter cells. These malformed daughter cells are now recognized by the immune system as foreign. An immune response occurs, and tumors are reduced. In one study of Glioblastoma (Brain Cancer) patients who took dexamethasone and had severely compromised immune systems got no benefit from TTF. Those patients with functioning immune systems had breakthrough responses. Doctors treating Glioblastoma patients who are on TTF are now advised to reduce the dose of Dexamethasone. As you know, in order for TTF to be affective the device needs to be worn. It is our belief that prescribing TTF in the presence or aftermath of harsh side effects from chemo reduces the patient’s ability to wear the needed TTF device. Their too tired and worn out. Although we plan on getting our device approved for the most difficult cases, we believe the best way to serve metastatic patients is to treat them when they are asymptomatic. The modern reoccurring metastatic patient is often brought into periods of remission. In today’s world new reoccurrences are often discovered through blood work (tumor markers) before any symptoms occur. This means we are presented with a patient with the healthiest immune system, best relative physical condition and most importantly, in most cases, relatively small tumors. This is an opportunity to introduce our adaptable form of TTF that can handle diffuse disease, bring that person back to remission and keep them in a long-term state of no symptoms from disease. Thus, making cancer a manageable disease. There are preclinical animal studies that show animals who even had a limited time on TTF experienced longer periods of time before the cancer returned compared to control groups. By repeating TTF as needed or as a prevention (perhaps on one week off two weeks) the science implies we can keep cancer in check. As our campaign continues we will ask Doctor Zehngebot our medical advisors to offer input as well. Again thank you for your insightful question.
- Q: last question. did you change your mind and decide not to do this raise. trying to figure out why they gave me a refund without me telling them to. I reached out to them not happy and they haven't responded. thanks for your time
- Q: I invested in your company. Payment was in process. The idiots at wefuhder gave me a refund even though I didn't even tell them to.
- Q: That's why you see companies say 99 percent or most. If something happens to one person they are getting sued. Look forward to the journey
- Q: you have with no side effects yet you name a possible side effect. a potential small one that is very treatable but one nonetheless. I would probably put no major side effects, possible minor side effects but very treatable. people are sue happy these days. if they tried your product and got a side effect doesn't matter how big or small they potentially would sue you for false advertising. thanks for time and I look forward to journey.
  - A: Thank you for raising this — it’s a fair and important point, and I appreciate you flagging it. You’re right that absolute statements can create unnecessary risk. When we say “no side effects,” what we mean — and what we should state more precisely — is no major or systemic side effects. As with any external medical device, there is the possibility of minor, localized skin irritation, which has been observed across the entire Tumor Treating Fields category. Importantly, those minor effects are well understood, manageable, and treatable, and they are not systemic or cumulative. Physicians familiar with TTFields generally agree that most skin issues seen with existing devices are driven largely by continuous adhesive patches that stay on for 3–4 days and prevent normal skin care, including showering. Our device is designed differently: It does not rely on long-term adhesive patches It is removed daily, allowing the skin to breathe and be cleaned Patients receive proactive skin-care guidance All patients sign informed consent documents outlining all potential side effects, including minor skin irritation In practice, this approach appears to meaningfully reduce skin issues. As one real-world example (not a claim, just experience), my wife wore an early version of our device using our application method for over 800 days with no skin irritation. So the most accurate way to describe our safety profile is exactly as you suggested: no major side effects, with possible minor, localized skin irritation that is typically very treatable. I appreciate you calling this out — precise language matters, especially today — and thank you for the thoughtful feedback and for being part of the journey.
- Q: I am going to invest just no where near what I would have if you were in it for the long term. last question, what kind of roi multiple are you shooting for for investors? I see you are shutting down very soon. thanks
  - A: Thanks for the candid question — I appreciate you raising it. On return expectations: we don’t target or promise a specific ROI multiple. This is a regulated oncology medical device company, and outcomes depend on clinical data, regulatory progress, and execution. For context only, there are comparable oncology and Class III medical device companies that, after reaching meaningful clinical validation and attracting strategic interest, ultimately delivered investor outcomes in the ~30x to 60x range. Those outcomes were driven by clear clinical signals, defensible IP, and very large unmet markets — not by short-term fundraising events. It’s important to emphasize that these are historical outcomes, not projections, and that not every program achieves them. Oncology and Class III medical devices carry real risk, and investors should size their participation accordingly. Our focus at LifeBridge is to build toward the same types of value-creating milestones — safety validation, early human data, strong IP, and a large metastatic cancer market — step by step and with discipline. Happy to clarify anything further.
- Q: oh I didn't know your goal was just to finish trials and exit. i assumed your goal was to turn the company into a billion dollar company etc. thanks for your time
  - A: Thank you
- Q: amazing! love this! great per share price and valuation, you have something huge here. you and Rick did a great job explaining how you are different and what you offer. tomorrow I am investing in a bunch of medical clinics, therefore, very intriguing. i have a few questions. see your raise is closing in a few days so let me get right to it. 1. so just to be sure. this can be paid by medicare etc? if so let's say patient don't have insurance do you know how much it will cost patient? 2. do you know yet how much this will cost clinics, hospitals or will this be more the doctors recommend you to patients. if that is the case will you give them a referral, how will that work. a referral program type thing? 3. I know you are still going through trials etc but do you have any projected revenue numbers or too early to even think about that? 4. do you see yourself having to raise money again and if so what for. another clinical trial etc? thanks for your time and again great job!
  - A: Hello John, thank you for your questions. 1. The present form of TTF has gained 3rd party reimbursement globally, including by Medicare in the U.S. We expect our advanced system to do the same. As a monotherapy, without side effects we expect to document less ER visits and home care issues, which should make us attractive to insurance companies. For noninsured patients the cost is projected to be similar to existing chemo therapies, but our final cost is yet to be determined. We hope whoever purchases our company will provide special programs for the uninsured. 2. We do not yet know what our cost will be, although we run our estimates at cost similar to most Chemo therapies. Oncologists will prescribe our therapy. However, it is unlikely there will be referral fees. Most Oncologist are on salary today from larger health care systems. 3. The most likely scenario for LifeBridge is that it will be purchased after our human clinical trial is completed in 24 to 36 months. This will allow a larger company to finish the final trial more quickly and take the therapy global. Other oncology companies that have sold at that stage have done extremely well for their investors and for those who need the therapy the most. LifeBridge has multiple global companies following our progress. 4. We are in the middle of our 5 million dollar raise, this should be enough for us to complete our pilot human trial and exit. Thank you again for your thoughtful questions.
- Q: You say you have your products in 3000 hospitals. My question is whether the products have lived up to your expectations. How many patients have benefitted from the deployment of your products? What is the reaction of the hospitals?
  - A: Hello Thank you for your question. The reference to 3,000 hospitals is in the section about what the LifeBridge team has accomplished in their careers in the past, not what has happened with the LifeBridge therapy. From accredited investors we have recently raised 2 million dollars, which is enough to finish our FDA requirements to open our human pilot study the 4th quarter of 2026.
- Q: Is the $3.7m Reg D funding raised off WeFunder in the current round? In other words is it now cash in the bank or pending disbursement? This is an impressive raise and I hope it helps take the technology through the next stage of development.
  - A: Hello Iain, the $3.7m has been raised, and has been and continues to be actively used for getting us through the FDA process. The $3.7m was raised under the same terms as the Wefunder offer opened now. Please let me know if you have any additional questions. Thank you Peter Travers CEO